



Workshop "Meet the Professor"

UPDATE ON AML AND ALL

Bologna
September 30th
2024



AIM

Biological knowledges have revolutionized treatment of adult AML and ALL in the recent years, leading to improved long term cure rates. The introduction of targeted agents, and the development of new approaches, are allowing more and more patients to achieve deeper and more durable responses.

In this Workshop, we will firstly discuss and describe the development and the results of highly potent new approaches in AML, including new hypomethylating agents and innovative small molecules which are offering, alone or in combination with other agents, promising results. We'll also focus our attention on the potential mechanisms responsible for resistance to these strategies, trying to highlight how to overcome them, in the near future.

The second part of the workshop will address the topic of ALL, aiming at updating on the tremendous advances and progress made in the treatment of this rare disease in adult population. The introduction of antibodies, CAR-T cells, and more potent TKIs have strongly modified the therapeutic armamentarium of hematologists, leading to brilliant long term cure rates. However, their best positioning and many open questions are currently a matter of debate, and potential answers and future strategies will be presented.

CHAIRS:

Antonio Curti

IRCCS Azienda Ospedaliero Universitaria di Bologna, Istituto di Ematologia Seràgnoli, Bologna - Italy

Giovanni Martinelli

IRCCS Azienda Ospedaliero Universitaria di Bologna, Istituto di Ematologia Seràgnoli, Bologna - Italy


CO-CHAIRS:

Giovanni Marconi

Università di Bologna, Unità di Onco-ematologia Ospedale S. Maria delle Croci, Ravenna - Italy

Cristina Papayannidis

IRCCS Azienda Ospedaliero Universitaria di Bologna, Istituto di Ematologia Seràgnoli, Bologna - Italy



SEPTEMBER 30TH, 2024

2.00-2.30 p.m.

WELCOME AND KEYNOTE ADDRESS

Antonio Curti, Giovanni Martinelli

Moderators: G. Martinelli, V. Santini

2.30-3.00 p.m.

Meet the Professor:

What's new in AML therapy? Oral hypomethylating agents and beyond

Naval Daver

Leukemia Department, MD Anderson Cancer Center, Houston, USA

3.00-3.45 p.m.

Discussion

3.45-4.00 p.m.

Coffee break

Moderators: G. Marconi, C. Papayannidis

4.00-4.30 p.m.

Meet the Professor:

ALL treatment in 2024: goals achieved and open challenges

Elias Joseph Jabbour

Leukemia Department, MD Anderson Cancer Center, Houston, USA

4.30-5.15 p.m.

Discussion

5.15-5.35 p.m.

Moderators: D. Vallisa, V. Santini

New Targets in acute leukemias: from mutations to TAD-driven alterations

Anna Ferrari

IRST-IRCCS and CCCRN della Romagna, Meldola, Italy

5.35-6.00 p.m.

Q&A and Final Discussion.

Closing Remarks

G. Martinelli, A. Curti



INFORMATION

VENUE

NH Bologna De La Gare
P.za XX Settembre, 2
40121 Bologna

REGISTRATION

Registration for the event is free and should be done at the following link:

https://centercongressi.com/eventi/update_aml_all2024